Plasma and urine metabolic profiles are reflective of altered beta-oxidation in non-diabetic obese subjects and patients with type 2 diabetes mellitus by unknown
METABOLIC SYNDROME
DIABETOLOGY & 
Villarreal-Pérez et al. Diabetology & Metabolic Syndrome 2014, 6:129
http://www.dmsjournal.com/content/6/1/129RESEARCH Open AccessPlasma and urine metabolic profiles are reflective
of altered beta-oxidation in non-diabetic obese
subjects and patients with type 2 diabetes
mellitus
Jesús Zacarías Villarreal-Pérez1, Jesús Zacarías Villarreal-Martínez2, Fernando Javier Lavalle-González1,
María del Rosario Torres-Sepúlveda3, Consuelo Ruiz-Herrera3, Ricardo Martín Cerda-Flores4,
Erik Rubén Castillo-García3, Irám Pablo Rodríguez-Sánchez3 and Laura Elia Martínez de Villarreal3*Abstract
Objectives: The two primary pathophysiological characteristics of patients with type 2 diabetes mellitus (T2DM) are
insulin resistance (IR) and beta cell dysfunction. It has been proposed that the development of IR is secondary to
the accumulation of triacylglycerols and fatty acids in the muscle and liver, which is in turn thought to be
secondary to an enzymatic defect in mitochondrial beta-oxidation. The purpose of the present study was to analyze
the molecules of intermediary metabolism to determine if an alteration in mitochondrial function exists in T2DM
patients and, if so, to determine whether this alteration is caused by excess nutrients or an enzymatic defect.
Design and methods: Seventy-seven subjects were recruited and divided into four groups (21 T2DM patients, 17
non-diabetic overweight/obese subjects, 20 offspring of T2DM patients, and 19 healthy subjects). Anthropometric
parameters were determined by air plethysmography, and biochemical and metabolic parameters were measured,
including 31 acylcarnitines (ACs) and 13 amino acids quantified by MS/MS and 67 organic acids measured by GC/MS.
Results: Patients with T2DM showed elevation of short-chain ACs (C2, C4), a glycogenic amino acid (valine), a
glycogenic and ketogenic amino acid (tyrosine), and a ketogenic amino acid (leucine) as well as altered excretion
of dicarboxylic acids. T2DM offspring with abnormal glucose tolerance test GTT showed increased levels of C16.
Subjects in the obese group who were dysglycemic also showed altered urinary excretion of dicarboxylic acids
and lower levels of a long-chain AC (C14:2).
Conclusions: These results suggest that mitochondrial beta-oxidation is altered in T2DM patients and that the
alteration is most likely caused by nutrient overload through a different pathway from that observed in obese subjects.
Keywords: Acetylcarnitine, Butyrylcarnitine, T2DM, Beta-oxidation defect, Non-diabetic obese, Air plethysmographyIntroduction
Type 2 diabetes mellitus (T2DM) and obesity are two
deleterious metabolic conditions [1] whose incidence
has increased worldwide in the last decade [2]. Both diet
and sedentary lifestyle are important risk factors for their
development [3]. In Mexico, 74% of the adult population* Correspondence: laelmar@yahoo.com.mx
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article, unless otherwise stated.is either overweight or obese, and 14.6% suffer from
T2DM [4], which has a high morbidity and mortality [2].
The primary pathophysiological characteristics in T2DM
are insulin resistance (IR) and beta-cell dysfunction
[5,6]. IR is considered to be a state in which peripheral
tissues are rendered unresponsive to the glucose lower-
ing, antilypolytic, and anabolic properties of insulin,
which is a hallmark of obesity and T2DM. IR is also ac-
cepted as an early feature of T2DM because it typically
appears one or two decades before the manifestation of
clinically overt diabetes [6].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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accumulation of triacylglycerols and fatty acids in the
muscle and liver (lipotoxicity theory) [6]. Although
the molecular pathogenesis of lipotoxicity is not clear, it
has been proposed that it occurs secondary to altered
mitochondrial function, resulting from a decline in beta-
oxidation, an excess of non-esterified fatty acids arriving
at the mitochondria, or both [7]. Several reports indicate
that there is an increased rate of beta-oxidation in obese
individuals as well as in T2DM patients in a feeding
state, whereas the rate of beta-oxidation is reduced dur-
ing fasting [8]. Although the mechanisms of this reduc-
tion are unknown, it has been proposed that inhibition
of carnitine palmitoyltransferase-1 (CPT1) as a result of
increasing levels of malonyl coenzyme A (malonyl CoA)
could be responsible for the decreased beta-oxidation
activity [9]. Recent studies have suggested that lipid ac-
cumulation results from a lower oxidative capacity of
the mitochondria [7] or reduced activity of the tricarb-
oxylic acid cycle [6]. Another possible explanation for
this reduction in beta-oxidation is an excessive increase
in the delivery of fatty acids to the mitochondria [10].
Defects in the beta-oxidation of fatty acids can be eval-
uated based on acylcarnitine (AC) levels measured by
tandem mass spectrometry, which is widely used in neo-
natal screening for fatty acid oxidation disorders and or-
ganic acidemias [11,12].
This methodology has also been used to analyze mito-
chondrial function in diabetic patients. Recent reports
indicate that there is an increase in the levels of long-,
medium-, and short-chain ACs in the blood of patients
with T2DM and an elevation of long-chain ACs in obese
subjects [13].
We designed this study to quantify intermediate me-
tabolites in plasma and urine to determine if they reflect
a beta-oxidation defect in patients with T2DM and obese
individuals and to determine whether an excess of nutri-
ents or a blockage of beta-oxidation is the cause of the
alteration. Additionally, we postulated that if there is an
alteration in mitochondrial function in T2DM patients,
it should be present before T2DM presents; for this rea-




We performed a descriptive, comparative, non-blinded
study that included 77 subjects (21 T2DM patients, 17
non-diabetic overweight/obese subjects, 20 non-diabetic
offspring of T2DM patients [the latter two groups have a
higher risk of developing T2DM], and 19 healthy subjects).
Subjects with diabetes were recruited during 2010 from
the outpatient diabetes clinic of the Endocrinology Service
of the Dr. José E González University Hospital, UniversidadAutónoma de Nuevo León (UANL), Monterrey, México.
Volunteer participants were recruited from the University
Hospital and Medical School population, either as subjects
at risk for developing T2DM (overweight/obese and off-
spring of T2DM patients) or as controls. Written informed
consent was obtained from all subjects, and the Health
Research Ethics Board of the UANL Medical School ap-
proved the study (Approval #: EN-10-030).
Men and women over 18 years of age were included.
Participants were assigned to one of four groups: 1) pa-
tients with T2DM diagnosed according to the criteria
established by the American Diabetes Association; 2)
non-diabetic subjects considered to be overweight/obese
with a body mass index (BMI) ≥25 kg/m2 and without a
history of T2DM in a first-degree relative; 3) non-
diabetic individuals who had at least one parent diag-
nosed with T2DM; and 4) healthy individuals with a nor-
mal BMI (>20 and <25 kg/m2), a normal oral glucose
tolerance test (OGTT), and no history of T2DM. The
group of healthy subjects was designated as the control
group. T2DM patients were required to discontinue
medication (oral hypoglycemic drugs) and should not
have received any insulin the night before the study.
Anthropometric, biochemical, and metabolic parameters
Body composition was obtained by air impedance pleth-
ysmography (BOD POD). For the biochemical parame-
ters, 30 mL of venous blood was collected after a 12- to
14-hour fast. Glucose levels, free fatty acids (FFAs), insu-
lin, transaminases (AST, ALT), uric acid, urea nitrogen,
cholesterol, and alkaline phosphatase as well as a lipid
profile were examined in serum or plasma, depending
on the kit used. The Homeostasis Model Assessment
(HOMA) and Matsuda indices were calculated [14].
Blood samples were collected from all subjects to meas-
ure the levels of 31 ACs, 13 amino acids, pyruvate, lactate,
and ketone bodies. An OGTT (standardized fasting) was
performed in all groups except for the T2DM group. For
AC quantification, blood samples were collected on filter
paper (SS903) and analyzed by tandem mass spectrometry
(MS/MS, API 2000, Perkin Elmer Sciex; full-scan, multiple-
scan monitoring (MRM)).
A urine sample was collected for the measurement of 67
organic acids with a gas chromatograph/mass spectrometer
(CLARUS 500, Perkin-Elmer Corporation, Norwalk, CT,
USA). The procedure for the extraction of organic acids
consisted of calculating the sample volume, then adjusting
the volume according to creatinine excretion, which should
be twice the volume containing 0.06 mg/100 g creatinine.
Urinary organic acids were determined by oximation.
Extraction was performed with ethyl acetate. Derivatization
was performed by adding BSTFA-1% TMCS (N, O-bis (tri-
methylsilyl) trifluoroacetamide with 1% trimethylchlorosi-
lane) and heating to 60°C in a water bath. Following this,
Table 1 Comparison of anthropometric and biochemical





(n = 21) (X + SD)
Age 52 ± 11.1 24.3 ± 3.7 <0.005
BMI 32.4 ± 6.0 22.8 ± 1.4 <0.005
Waist cm 103.3 ± 13.8 70.0 ± 7.7 <0.005
Hip cm 109.0 ± 13.3 95.0 ± 7.7 <0.005
% Fat 42.0 ± 8.9 25.6 ± 9.8 <0.005
% Lean mass 58.0 ± 9.0 74.3 ± 9.9 <0.005
Total weight 84.2 ± 17.1 63.1 ± 9.2 <0.005
Glucose 0´ 148.2 ± 51.4 83.9 ± 12.5 <0.005
Glucose 30´ ND ND ND
Glucose 60´ ND ND ND
Glucose 90´ ND ND ND
Glucose 120´ ND ND ND
Insulin 0´ 15.6 ± 7.9 7.3 ± 2.0 <0.005
HOMA IR 5.4 ± 2.7 1.5 ± 0.44 <0.005
Free fatty acids 0.6 ± 0.2 0.5 ± 0.3 >0.05
Beta-hydroxybutyrate 0.2 ± 0.1 0.2 ± 0.04 >0.05
ALP 63 ± 17 62.10 ± 16.9 >0.05
Uric acid 5.8 ± 1.5 5.2 ± 1.0 >0.05
Serum creatinine 0.7 ± 0.17 0.8 ± 0.15 >0.05
Cholesterol 202.5 ± 50.7 200.6 ± 39.6 >0.05
Total bilirubin 0.2 ± 0.10 0.3 ± 0.2 >0.05
Direct bilirubin .05 ± .02 0.06 ± 0.03 >0.05
Indirect bilirubin 0.15 ± 0.1 0.2 ± 0.1 >0.05
Total protein 8.1 ± 0 .7 8.5 ± 0.9 >0.05
Albumin 4.7 ± 0.5 5.13 ± 0.5 <0.05
Globulin 3.4 ± 0.4 3.4 ± 0.5 >0.05
AST 17 ± 11.5 10.4 ± 2.0 <0.05
ALT 14.5 ± 10.1 8.0 ± 2.6 <0.005
C4 0.24 ± 0.10 0.18 + 0.08 <0.05
C2 10.1 ± 2.2 8.7 ± 1.6 <0.005
Leu 117.7 ± 22.3 96.1 ± 23.7 <0.05
Tyr 51.3 ± 10.4 41.5 ± 11.0 <0.005
Val 165.2 ± 19.0 135.0 ± 31.0 <0.005
Gly 242.0 ± 36.2 226.5 ± 47.0 >0.05
Arg 27.5 ± 9.8 27.4 ± 7.8 >0.05
Cit 18.4 ± 4.7 17.5 ± 4.2 >0.05
Met 21.7 ± 5.1 22.4 ± 5.2 >0.05
Orn 83.7 ± 13.8 76.6 ± 9.6 >0.05
Phe 41.2 ± 6.2 39.3 ± 10.8 >0.05
Ala 288.8 ± 63.0 238.0 ± 44.2 <0.005
NOTE: Parameters in bold were significant.
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graph. Finally, spectral analysis and identification were per-
formed using the NIST MS Search Program Version 2.0.
Statistical analysis
Each study group was compared with the control group.
For quantitative parameters, Student´s t-test was used,
whereas Fisher´s exact test was used for qualitative mea-
surements. A P <0.05 was defined as significant. IBM
SPSS 20 statistical software (IBM Corporation, Somers,
NY) was used for data analysis.
Results
In total, 111 biochemical and metabolic parameters, in-
cluding ACs, amino acids, and organic acids, were mea-
sured in all groups. Comparison of the study groups
with the control group showed that in the three groups
of cases, the average BMI, anthropometric parameters
obtained by BOD POD, and ages were higher.
Tables 1, 2, and 3 provide the biochemical parameters
and metabolites that displayed significant differences be-
tween the case groups and the control group. Regarding
biochemical parameters, subjects with T2DM had basal
glucose, insulin levels, and ketone bodies levels in blood
and a HOMA index that were significantly higher than
those of healthy controls. Triacylglycerol, acetylcarnitine
(C2), butyrylcarnitine (C4), alanine, tyrosine, and the
branched chain amino acids leucine and valine (Table 1)
were also significantly elevated in this group.
In addition to differences in anthropometric measure-
ments, non-diabetic overweight/obese subjects only had an
increased HOMA index; we did not observe elevations of
triacylglycerols, amino acids, or ACs (Table 2). In this group,
six (35.3%) patients with pre-diabetes (basal glucose = 101 -
125 mg/dl and/or OGTT 120 min = 141 - 199 mg/dl)
showed a decrease in the level of C14:2 (tetradecenoyl car-
nitine) in addition to glucose elevations at 30, 60, 90, and
120 min during the OGTT and elevation of insulin levels
at 120 min compared with the control group (Table 4).
The non-diabetic offspring of T2DM patients showed
higher blood glucose levels during the OGTT at 60 and
120 min as well as increased insulin levels at 0, 60, 90,
and 120 min relative to the control group (Table 3).
Additionally, the Matsuda and HOMA indices were
lower and higher, respectively, as compared to control
group (Table 3). In this group, 14 (66%) patients were
overweight/obese, and 5 (25%) were pre-diabetic. The
pre-diabetic offspring exhibited a significant elevation of
palmitoylcarnitine (C16) and decreased glycine as well
as significant differences in anthropometric measure-
ments, insulin at time 0, and the HOMA index relative
to the control group (Table 4).
All case groups demonstrated a significant elevation
of transaminases (AST and ALT), although uric acid
Table 2 Comparison of anthropometric and biochemical
measurements in the overweight/obese patient group





(n = 17) (X + SD)
Age 39.2 ± 14.0 24.3 ± 3.7 <0.005
BMI 30.2 ± 7.4 22.8 ± 1.4 <0.005
Waist cm 99.1 ± 17.6 70.0 ± 7.7 <0.005
Hip cm 111.3 ± 11.8 95.0 ± 7.7 <0.005
% Fat 37.3 ± 11.4 25.6 ± 9.8 <0.005
% Lean mass 62.7 ± 11.4 74.3 ± 9.9 <0.005
30.6 ± 12.1 18.1 ± 11.7 <0.005
Total weight 84.1 ± 17.3 63.1 ± 9.2 <0.005
Glucose O´ 90.5 ± 11.9 83.9 ± 12.5 >0.05
Glucose 30´ 144.2 ± 34.6 131 ± 30.9 >0.05
Glucose 60´ 126.5 ± 53.5 113.9 ± 25.3 >0.05
Glucose 90´ 120.5 ± 48.8 109.27 ± 33.33 >0.05
Glucose 120´ 107.6 ± 46.4 94.9 ± 21.7 >0.05
Insulin 0´ 10.7 ± 7.0 7.3 ± 2.0 >0.05
Insulin 30´ 81.4 ± 51.5 56.7 ± 24.6 >0.05
Insulin 60´ 89.9 ± 92.4 57.9 ± 36.2 >0.05
Insulin 90´ 72.9 ± 63.3 54.8 ± 35.8 >0.05
Insulin 120´ 76.3 ± 69.67 41.4 ± 37.0 >0.05
Matsuda index 4.9 ± 2.5 6.2 ± 1.8 >0.05
HOMA IR 2.3 ± 1.3 1.5 ± 0.44 <0.05
Free fatty acids 0.5 ± 0.20 0.5 ± 0.3 >0.05
Beta-hydroxybutyrate 0.2 ± 0.05 0.2 ± 0.3 >0.05
ALP 57.9 ± 13.1 62.16 + 16.9 >0.05
Uric acid 6.3 ± 1.4 5.2 ± 1.0 <0.05
Serum creatinine 0.9 ± 0.3 0.8 ± 0.15 >0.05
Cholesterol 214.0 ± 66.8 200.6 ± 39.6 >0.05
Total bilirubin 0.4 ± 0.3 0.3 ± 0.2 >0.05
Direct bilirubin 0.05 ± 0.03 0.06 ± 0.03 >0.05
Indirect bilirubin 0.3 ± 0.26 0.2 ± 0.18 >0.05
Total protein 8.2 ± 1.07 8.5 ± 0.9 >0.05
Albumin 4.9 ± 0.4 5.1 ± 0.5 >0.05
Globulin 3.3 ± 0.62 3.4 ± 0.5 >0.05
AST 16.1 ± 9.3 10.4 ± 2.0 <0.05
ALT 10.4 ± 3.3 8.2 ± 2.6 <0.05
C4 0.19 ± 0.11 0.18 ± 0.08 >0.05
C2 8.5 ± 2.3 8.7 ± 1.6 >0.05
Leu 95.3 ± 28.0 103.8 ± 21.5 >0.05
Tyr 43.4 ± 10.8 48.2 ± 10.5 >0.05
Val 126.1 ± 41.7 138.8 ± 34.2 >0.05
Gly 210.8 ± 54.1 220.6 ± 38.4 >0.05
Arg 24.3 ± 10.5 24.1 ± 6.25 >0.05
Table 2 Comparison of anthropometric and biochemical
measurements in the overweight/obese patient group
and the control group (Continued)
Cit 17.7 ± 4.1 17.9 ± 6.25 >0.05
Met 21.26 ± 5.7 23.5 ± 6.25 >0.05
Orn 85.5 ± 23.4 80.2 ± 15.0 >0.05
Phe 38.2 ± 8.5 41.1 ± 8.3 >0.05
Ala 209.9 ± 52.4 238. ± 45.2 >0.05
NOTE: Parameters in bold were significant.
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spring groups.
Analysis of the organic acids in urine showed the pres-
ence of intermediate metabolites of glycolysis and the
Krebs cycle including lactic, 3OH-butyric, succinic,
adipic, palmitic, citric, and phenyl acetic acids in all sub-
jects in all four groups. Some metabolites were detected
in a limited number of study participants. A significantly
higher proportion of subjects with T2DM excreted
2OH-butyric acid relative to the control group (90% vs.
20%, P <0.05), and none exhibited sebacic acid excretion,
compared with 40% in the control group (P <0.05). A
lower number of obese subjects excreted suberic acid
relative to the control group (36% vs. 89%, P <0.05).
There were no differences in the excretion of organic
acids between the offspring of T2DM patients and the
control group.
Discussion
The present study was conducted to obtain more infor-
mation regarding biochemical and metabolic parameters
in T2DM patients and to compare these parameters with
healthy subjects to determine whether altered mitochon-
drial beta-oxidation, secondary to either an overload of
nutrients or an enzymatic defect, exists in these patients.
Additionally, the study examined whether subjects at
risk for developing T2DM present metabolic alterations
prior to developing the disease.
In the present study all the anthropometric parameters
(i.e., BMI, waist, %fat) were significantly higher in the in-
dividuals of the case groups when comparing against the
control group. However, only the offspring of T2DM pa-
tients showed altered plasma glucose and insulin levels
during the OGTT; obese subjects did not.
In the biochemical measurements, transaminases (AST,
ALT) were significantly higher in all case groups than in
controls. It has been reported that individuals with T2DM
have a higher incidence of liver function test abnormalities
than individuals who do not have diabetes. Additionally,
mild chronic elevations of transaminases often reflect
underlying insulin resistance [15].
The elevation of transaminases in diabetics, overweight/
obese individuals, and offspring of diabetic patients found
Table 3 Comparison of anthropometric and biochemical








(n = 20) (X + SD)
Age 37.15 ± 13.4 24.3 ± 3.7 <0.005
BMI 29.3 ± 6.0 22.8 ± 1.4 <0.001
Waist cm 95.3 ± 17.1 70.0 ± 7.7 <0.0005
Hip cm 106.0 + 17.7 95.0 ± 7.7 <0.005
% Fat 32.5 ± 11.2 25.6 ± 9.8 <0.05
% Lean mass 67.5 ± 11.2 74.3 ± 9.9 <0.05
Total weight 82.54 ± 21.67 63.1 ± 9.2 <0.0005
Glucose O 90.25 ± 11.47 83.9 ± 12.5 >0.05
Glucose 30´ 140.7 ± 32.76 131 ± 30.9 >0.05
Glucose 60´ 141.2 ± 40.0 113.9 ± 25.3 <0.05
Glucose 90´ 128.5 ± 46.46 109.27 ± 33.33 >0.05
Glucose 120 120.05 ± 33.21 94.9 ± 21.7 <0.005
Insulin 0´ 11.1 ± 4.9 7.3 ± 2.0 <0.0005
Insulin 30´ 80.7 ± 49.8 56.7 ± 24.6 <0.05
Insulin 60´ 87.7 ± 58.3 57.9 ± 36.2 <0.05
Insulin 90´ 79.4 ± 57.2 54.8 ± 35.8 <0.05
Insulin 120´ 73.2 ± 49.6 41.4 ± 37.0 <0.0005
Free fatty acids 0.62 ± 0.24 0.5 ± 0.3 >0.05
Beta-hydroxybutyrate 0.18 ± 0.10 0.2 ± 0.3 >0.05
ALP 58.5 + 20.17 58.6 ± 20.2 >0.05
Uric acid 6.21 ± 1.33 5.2 ± 1.0 <0.05
Serum creatinine 0.91 ± 0.17 0.8 + 0.15 >0.05
Cholesterol 198.65 ± 28.4 200.6 ± 39.6 >0.05
Total bilirubin 0.34 ± 0.21 0.3 ± 0.2 >0.05
Direct bilirubin 0.05 ± 0.04 0.06 ± 0.03 >0.05
Indirect bilirubin 0.28 ± 0.21 0.2 ± 0.18 >0.05
Total protein 8.38 ± 0.80 8.4 ± 0.9 >0.05
Albumin 4.98 ± 0.39 5.11 ± 0.5 >0.05
Globulin 3.39 ± 0.55 3.4 ± 0.5 >0.05
AST 14.85 ± 8.64 10.4 ± 2.0 <0.05
ALT 13.7 ± 8.11 8.2 ± 2.6 <0.0005
Triacylglycerol 154.2 ± 114.9 110.6 ± 71.2 >0.05
C4 0.17 ± 0.08 0.18 ± 0.08 >0.05
C2 9.14 ± 1.44 8.7 ± 1.6 >0.05
Leu 103.8 ± 21.52 96.1 ± 23.7 >0.05
Tyr 48.2 ± 10.5 41.5 ± 11.0 >0.05
Val 138.8 ± 34.2 135.0 ± 31.0 >0.05
Gly 220.6 ± 38.4 226.5 ± 47 >0.05
Arg 24.1 ± 7.3 27.4 ± 7.84 >0.05
Cit 17.9 ± 3.09 17.5 ± 4.2 >0.05
Met 23.5 ± 6.25 22.4 ± 5.2 >0.05
Table 3 Comparison of anthropometric and biochemical
measurements in the T2DM patient offspring group and
the control group (Continued)
Orn 80.2 ± 15.0 76.6 ± 9.5 >0.05
Phe 41.1 ± 8.3 39.3 ± 10.8 >0.05
Ala 231.0 ± 45.23 238.0 ± 44.2 >0.05
NOTE: Parameters in bold were significant.
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the liver [16], although FFAs were not significantly ele-
vated. It has been previously reported that elevated ALT in
non-diabetic Swedish men is a risk factor for T2DM, inde-
pendent of obesity, body fat distribution, plasma glucose,
lipid, AST, bilirubin concentration, and family history of
diabetes. In another study, non-diabetic Pima Indians were
followed for an average of 6.9 years to determine whether
hepatic enzyme elevations could be linked to the develop-
ment of T2DM. At baseline, ALT, AST, and the OGTT
were related to percent body fat. After adjusting for age,
sex, body fat, whole body insulin sensitivity, and acute
insulin response, only elevated ALT at baseline was associ-
ated with an increase in hepatic glucose output. Prospect-
ively, increasing ALT concentrations were associated with a
decline in hepatic insulin sensitivity and risk of T2DM.
The authors concluded that higher ALT is a risk factor for
T2DM and indicates a potential role of increased hepatic
gluconeogenesis and/or inflammation in its pathogenesis
[15]. Our results are in agreement with the aforementioned
studies because only subjects with dysglycemia showed
increased ALT in the subgroup analysis of the over-
weight/obese and offspring groups. As expected T2DM
patients, showed high plasma triacylglycerol concentra-
tion, as well as disglycemic subjects from the obese and
offspring groups.
It has been reported that an overload of mitochondrial
lipid oxidation results in the accumulation of β-oxidation
intermediates (ACs) and the depletion of Krebs cycle inter-
mediates, leading to mitochondrial stress and activating
currently unknown signaling pathways that interfere with
insulin action [6]. Reports regarding the elevation of
β-oxidation intermediates in diabetics are controversial.
Shure et al. reported elevation of long-chain ACs and
decreased levels of short-chain ACs [17], whereas Adams
et al. and Mihalik et al. reported elevation of short-,
medium- and long-chain ACs in diabetic patients [13,18].
In a study with streptozotocin-induced diabetic rats, short-
chain ACs (C2 and C4) was significantly elevated In a re-
cent study, considerably higher levels of short-chain ACs
and lower levels of some long-chain ACs were detected in
T2DM patients and patients with metabolic syndrome [19].
In the present study, T2DM patients showed elevated
levels of short-chain ACs (C2 and C4) in the blood as
Table 4 Comparison of anthropometric and biochemical
measurements in the dysglycemic patient group and the
control group
Dysglycemic/obese








Age 53.0 ± 7.66* 46.6 ± 12.0* 24.3 ± 3.7
BMI 33.2 ± 8.28* 33.8 ± 6.7* 22.8 ± 1.4
Waist cm 99.9 ± 14.7* 109.0 ± 20.9* 70 ± 7.7
Hip cm 107.2 ± 8.7* 116.2 ± 24.5 95 ± 7.7
% Lean mass 66.8 ± 7.9 62.8 ± 15.1 74.3 ± 9.9
Total weight 87.2 ± 21.8* 95.8 ± 26.0* 63.1 ± 9.2
Glucose O´ 97.2 ± 16.5 100.6 ± 8.8* 83.9 ± 12.5
Glucose 30´ 169.7 ± 35.3* 177 ± 39.91 131 ± 30.9
Glucose 60´ 182.8 ± 55.0* 196.2 ± 23.8* 113.9 ± 25.3
Glucose 90´ 171.0 ± 42.8* 198.0 ± 38.5* 109.27 ± 33.33
Glucose 120´ 150.0 ± 45.9* 165.0 ± 20.92* 94.9 ± 21.7
Insulin 0´ 16.0 ± 9.6 12.6 ± 5.6 7.3 ± 2.0
Insulin 30´ 87.4 ± 42.6 98.7 ± 54.3 56.7 ± 24.6
Insulin 60´ 153.2 ± 135.6 126.2 ± 56.4* 57.9 ± 36.2
Insulin 90´ 130.3 ± 77.3 131.7 ± 59.0* 54.8 ± 35.8
Insulin 120´ 132.2 ± 84.1* 109.1 ± 46.0* 41.4 ± 37.0
Matsuda index 2.9 ± 2.1* 2.4 ± 1.0* 6.2 ± 1.8
HOMA IR 3.5 ± 1.5* 3.2 ± 1.5 1.5 ± 0.4
Free fatty acids 0.5 ± 0.3 0.7 ± 0.2 0.5 ± 0.3
Uric Acid 6.4 ± 1.4 7.12 ± 0.6* 5.2 ± 1.0
Serum Creatinine 0.9 ± 0.3 0.9 ± 0.2 0.8 ± 0.15
Cholesterol 234.5 ± 22.7* 180.8 ± 21.5 200.6 ± 39.6
AST 16.5 ± 7.6 18.2 ± 10.8 10.4 ± 2.0
ALT 12.0 ± 3.2* 19.4 ± 9.9 8.2 ± 2.6
Triacylglycerol 204.8 ± 80.0* 283.6 ± 177.3 110.6 ± 71.2
C4 0.18 ± 0.08 0.25 ± 0.13 0.18 ± 0.08
C2 8.4 ± 1.6 9.8 ± 1.05 8.7 ± 1.6
C16 0.74 ± 0.17 0.85 ± 0.14* 0.67 ± 0.17
C 14:2 0.03 ± 0.02* 0.05 ± 0.03 0.06 ± 0.3
*P value: <0.05.
NOTE: Parameters in bold were significant.
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http://www.dmsjournal.com/content/6/1/129compared to healthy controls. Disglycemic offspring
showed elevation of a long-chain AC (C16). Notably, in
contrast to these groups, dysglycemic obese patients
had lower levels of a specific long-chain AC (C14:2),
which suggests the involvement of the same metabolic
systems in a different manner, as postulated by Bene
et al. 2013 [19].
Acetylcarnitine (C2) is the final metabolite of the beta-
oxidation pathway, which produces acetyl CoA as a sub-
strate for the Krebs cycle, whereas butyrylcarnitine (C4)is a marker of ketogenesis and mitochondrial beta-
oxidation. C4 levels reflect the concentration of tissue
butyryl CoA, which is a metabolite of glutamate and
alpha-ketoglutarate, both of which are intermediate me-
tabolites of the Krebs cycle [20]. These findings exclu-
sively in the T2DM group would indicate an increase in
mitochondrial beta-oxidation [21].
We believe that the differences in the levels of ACs
found in the aforementioned studies, may be the result
of the conditions or characteristics of the patients at the
time of the study. In a previous study (unpublished re-
sults), we observed elevations of short-, medium-, and
long-chain ACs in individuals with diabetes; however, in
that study, patients had overt diabetes and were naive to
treatment, which is in contrast to the patients in the
present study, who were under treatment, and the differ-
ences among the reported studies could be related to the
time of diagnosis, drug use, or BMI.
The AC profile is used in neonatal screening as an
early marker of fatty acid disorders such as beta-
oxidation enzymatic defects. The results of the present
study do not support the hypothesis that there is an en-
zymatic defect in beta-oxidation that leads to fatty acid
accumulation and precludes IR because the earlier mani-
festations of beta-oxidation overload were observed in
the offspring of T2DM patients, who were already pre-
diabetic. The pre-diabetic offspring showed significant
elevation of long-chain fatty acid (C16) concentrations,
whereas euglycemic offspring only showed a higher
HOMA index relative to the control group, which sug-
gests that some insulin resistance was already present.
However, the elevation of C16 could be an early marker
for the risk of developing diabetes, as previously re-
ported by Zhao et al. [22].
T2DM encompasses not only changes in glucose metab-
olism but also alterations in fatty acid and protein levels
with subsequent metabolic alterations in the pathways
involved [23]. The branched-chain amino acids (BCAAs)
leucine and valine are glycogenic and modulators of insu-
lin secretion. According to Wang et al. [17], hyperaminoa-
cidemia can promote diabetes via hyperinsulinemia.
In a previous report, Vannini P et al. reported that the
BCAAs leucine and valine were increased in diabetic pa-
tients, indicating impaired short-term metabolic control [24].
BCAAs contribute to glucose recycling via the glucose-
alanine cycle. Under normal conditions, alanine arising from
BCAA nitrogen likely accounts for 25% of gluconeogenesis
from amino acids [25,26].
Elevation of BCAAs in IR adults independent of BMI in
conjunction with increases in plasma ACs derived from
amino acid oxidation suggests an increase in amino acid
flux [27]. In a recent report, leucine, valine, tyrosine, and
phenylalanine were found to be significantly associated
with the incidence of diabetes [28]. In the present study,
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sine, and alanine in diabetic patients, although in contrast
to the study of Wang, we did not find any association of
the amino acid concentration pattern with the prediction
of diabetes. Subjects in our study who were at risk for
developing diabetes (overweight/obese and the offspring
of T2DM subjects) did not show any increase in amino
acid levels. In a study with diabetic db-/db- mice, clear
evidence of increased gluconeogenesis was found, as
demonstrated by strongly decreased concentrations of the
gluconeogenic amino acids alanine, glycine, and serine
[15]. Although in the present study we observed increased
alanine in T2DM patients, dysglycemic obese subjects had
lower levels of glycine, perhaps as a sign of altered glucose
metabolism.
Obesity and a family history of T2DM are highly associ-
ated with development of the disease. The underlying
mechanisms that trigger and exacerbate obesity-associated
insulin resistance and the transition to T2DM remain un-
clear [29]. It has been suggested that a chronic positive en-
ergy balance and increased storage of energy as fat are
linked to impaired glucose homeostasis and the develop-
ment of diabetes [29]. Obesity is caused by the excessive
accumulation of triacylglycerols, and its effects on the use
and storage of various fuels (glucose, fatty acids, and
amino acids) result in abnormalities in metabolism [30].
In the present study, several analytes such as transami-
nases, glucose, and insulin were elevated in both the obese
group and the offspring group, which suggests that these
metabolic alterations are already present in both groups.
When we analyzed the pre-diabetic subjects, these meta-
bolic abnormalities were present, and markers of altered
mitochondrial beta-oxidation were also detected. We found
a lower level of unsaturated long-chain fatty acids (C14:2)
in the obese group, which could indicate a reduction in
long-chain fatty acid metabolism. Increases in short-,
medium-, and long-chain AC levels in diabetic individ-
uals suggest a different and more complex defect com-
pared with that of obese subjects.
Organic acids exist as intermediate compounds in many
biochemical pathways, (glycolysis, glyconeogenesis, lipoly-
sis). The Krebs cycle is the central metabolic pathway for
energy molecules, and deficiencies in any of the Krebs
cycle enzymes can cause inefficient cycling of organic acid
intermediates, which consequently increase their concen-
tration in the urine of the affected individual. In our study,
differential urinary excretion of dicarboxylic acids was ob-
served, whereas the excretion of adipic acid and 3OH-
butyrate, which are indicators of ketogenesis, was similar
in all groups. Ketosis is secondary to the fasting state and
is a metabolic marker of fatty acid metabolism that is ac-
companied by excessive urinary excretion of adipic (C6)
and suberic acids (C8) [31]. In the present study, a signifi-
cantly lower proportion of obese subjects excreted subericacid (C8) relative to the control group (36% vs. 89%), and
none of the T2DM patients excreted sebacic acid (C10).
This result could be related to a decrease in medium-
chain fatty acids in T2DM patients, which has been
reported previously [17].
The lack of sebacic acid (C10) excretion in diabetic
subjects would indicate active lipid metabolism, as this
has been reported in association with starvation, fat
feeding, or experimental diabetes [32], as well as an
elevated rate of beta-oxidation to form C6-C8 [33],
contrary to what we found in dysglycemic obese patients.
The increased urinary excretion of hydroxyisobutyric
acid in T2DM patients, which reflects an increase in
serum C4 levels (derived from fatty acid oxidation or
amino acid catabolism), indicates an increased metabol-
ism of fats or proteins.
Specific patterns were observed for each analyzed
group, and patients with T2DM had an abnormal AC
pattern that suggests an increase in the substrate for
mitochondrial beta-oxidation. This alteration could be
present at earlier stages of the disease because pre-
diabetic T2DM offspring showed increased levels of
C16. The group of obese subjects also showed altered
urinary excretion of dicarboxylic acids and lower levels
of the long-chain AC C14:2 when pre-diabetic, suggest-
ing altered mitochondrial beta-oxidation. Our results are
in agreement with those reported by Koves, et al. (6),
who suggested that there is a mitochondrial substrate
overload in T2DM patients.Conclusion
Patients with T2DM exhibit defective beta-oxidation that
suggests an overload of nutrients, as shown by higher
levels of TGL and elevation of acetylcarnitine and butyryl-
carnitine (both of which are derived from the final prod-
ucts of beta-oxidation) as well as augmented urinary
excretion of intermediate metabolites. This beta-oxidation
defect could be present at earlier stages of the disease be-
cause the pre-diabetic offspring of T2DM patients showed
increased levels of C16. Moreover, obese subjects also
showed altered mitochondrial beta-oxidation as well as al-
tered urinary excretion of dicarboxylic acids and reduced
levels of C14:2 only when disglycemic, indicating differen-
tial involvement of the metabolic pathways.
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